Impaired myocardial perfusion and perfusion reserve associated with increased coronary resistance in persistent idiopathic atrial fibrillation.

Symptoms and functional status of patients with atrial fibrillation: state of the art and future research opportunities. Circulation (2012) 1.67

Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles. Eur Heart J (2009) 0.96

Dronedarone prevents microcirculatory abnormalities in the left ventricle during atrial tachypacing in pigs. Br J Pharmacol (2012) 0.85

Atrial fibrillation: effects beyond the atrium? Cardiovasc Res (2015) 0.84

Oxidative Stress and Microcirculatory Flow Abnormalities in the Ventricles during Atrial Fibrillation. Front Physiol (2012) 0.79

Atrial fibrillation in heart failure: an innocent bystander? Curr Cardiol Rev (2012) 0.79

Reduced myocardial perfusion in atrial fibrillation: when the egg comes before the chicken. Eur Heart J (2007) 0.75

Protective effect of Suxiao jiuxin pill, a traditional Chinese medicine, against acute myocardial ischemia in dogs. BMC Complement Altern Med (2015) 0.75

Atrial fibrillation in heart failure: The sword of Damocles revisited. World J Cardiol (2013) 0.75

Biomarkers in electrophysiology: role in arrhythmias and resynchronization therapy. J Interv Card Electrophysiol (2015) 0.75

Symptoms In Atrial Fibrillation: A Contemporary Review And Future Directions. J Atr Fibrillation (2016) 0.75

Lone Atrial Fibrillation: Risk Factors, Triggers And Ablation Techniques. J Atr Fibrillation (2015) 0.75

Sodium-calcium exchange mediated contraction in left anterior descending and left ventricular branch arteries. J Cell Mol Med (2009) 0.75

Microvascular dysfunction in nonfailing arrhythmogenic right ventricular cardiomyopathy. Eur J Nucl Med Mol Imaging (2011) 0.75

[Rate versus rhythm control with and without heart failure]. Herz (2008) 0.75

Perspectives and challenges of antioxidant therapy for atrial fibrillation. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.75

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation (2010) 6.71

Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet (2012) 5.00

Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet (2003) 4.68

Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2005) 4.46

Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J (2010) 4.13

Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation (2012) 4.10

Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat Genet (2004) 3.88

Arrhythmogenic right ventricular cardiomyopathy/dysplasia clinical presentation and diagnostic evaluation: results from the North American Multidisciplinary Study. Heart Rhythm (2009) 2.82

Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J (2004) 2.78

Implantable cardioverter/defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy: single-center experience of long-term follow-up and complications in 60 patients. Circulation (2004) 2.77

Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol (2012) 2.77

Age- and training-dependent development of arrhythmogenic right ventricular cardiomyopathy in heterozygous plakoglobin-deficient mice. Circulation (2006) 2.76

Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med (Berl) (2004) 2.68

High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation (2006) 2.58

Genotype-phenotype relationship in Brugada syndrome: electrocardiographic features differentiate SCN5A-related patients from non-SCN5A-related patients. J Am Coll Cardiol (2002) 2.58

The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace (2009) 2.52

Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. Lancet (2002) 2.49

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet (2012) 2.43

HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest (2004) 2.36

Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace (2012) 2.30

Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT. J Nucl Med (2012) 2.25

Sodium channel gene (SCN5A) mutations in 44 index patients with Brugada syndrome: different incidences in familial and sporadic disease. Hum Mutat (2003) 2.24

Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol (2013) 2.17

Pacemaker channel dysfunction in a patient with sinus node disease. J Clin Invest (2003) 2.14

The ajmaline challenge in Brugada syndrome: diagnostic impact, safety, and recommended protocol. Eur Heart J (2003) 2.10

Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J (2008) 2.09

Role of programmed ventricular stimulation in patients with Brugada syndrome: a meta-analysis of worldwide published data. Eur Heart J (2007) 1.98

A novel dominant mutation in plakoglobin causes arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet (2007) 1.91

Real-life observations of clinical outcomes with rhythm- and rate-control therapies for atrial fibrillation RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation). J Am Coll Cardiol (2011) 1.91

Dynamic regulation of MEK/Erks and Akt/GSK-3beta in human end-stage heart failure after left ventricular mechanical support: myocardial mechanotransduction-sensitivity as a possible molecular mechanism. Cardiovasc Res (2003) 1.91

Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J (2007) 1.90

The diagnostic imaging of bone metastases. Dtsch Arztebl Int (2014) 1.83

Chronic kidney disease in patients with chronic heart failure--impact on intracardiac conduction, diastolic function and prognosis. Int J Cardiol (2006) 1.80

Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome. J Cardiovasc Electrophysiol (2007) 1.79

Long-term prognosis of individuals with right precordial ST-segment-elevation Brugada syndrome. Circulation (2005) 1.78

Detection of respiratory tumour motion using intrinsic list mode-driven gating in positron emission tomography. Eur J Nucl Med Mol Imaging (2010) 1.69

Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes. J Cardiovasc Electrophysiol (2007) 1.68

Mutant desmocollin-2 causes arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet (2006) 1.68

Cardiac autonomic dysfunction in Brugada syndrome. Circulation (2002) 1.68

A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. Eur Heart J (2011) 1.67

Quantitative assessment of angiographic right ventricular wall motion in arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C). J Cardiovasc Electrophysiol (2007) 1.65

Load-reducing therapy prevents development of arrhythmogenic right ventricular cardiomyopathy in plakoglobin-deficient mice. J Am Coll Cardiol (2011) 1.65

Gene dose-dependent atrial arrhythmias, heart block, and brady-cardiomyopathy in mice overexpressing A(3) adenosine receptors. Cardiovasc Res (2004) 1.60

Knock-in gain-of-function sodium channel mutation prolongs atrial action potentials and alters atrial vulnerability. Heart Rhythm (2010) 1.59

Idiopathic atrial fibrillation revisited in a large longitudinal clinical cohort. Europace (2011) 1.57

Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation (2004) 1.57

Autonomic trigger patterns and anti-arrhythmic treatment of paroxysmal atrial fibrillation: data from the Euro Heart Survey. Eur Heart J (2008) 1.57

Heart rate recovery in migraine and tension-type headache. Headache (2007) 1.57

Impact of sympathetic innervation on recurrent life-threatening arrhythmias in the follow-up of patients with idiopathic ventricular fibrillation. Eur J Nucl Med Mol Imaging (2006) 1.55

Diastolic isthmus length and 'vertical' isthmus angulation identify patients with difficult catheter ablation of typical atrial flutter: a pre-procedural MRI study. Europace (2008) 1.54

Acute inhibition of the Na(+)/Ca(2+) exchanger reduces proarrhythmia in an experimental model of chronic heart failure. Heart Rhythm (2011) 1.54

Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J (2013) 1.53

Prognostic significance of (18)F-FDG and (99m)Tc-methylene diphosphonate uptake in primary osteosarcoma. J Nucl Med (2002) 1.53

Chronic electrical stimulation during the absolute refractory period of the myocardium improves severe heart failure. Eur Heart J (2004) 1.52

Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol (2006) 1.51

Implantable cardioverter-defibrillator therapy in patients with congenital long-QT syndrome: a long-term follow-up. Heart Rhythm (2005) 1.50

Long-term support of 9 patients with the DeBakey VAD for more than 200 days. J Thorac Cardiovasc Surg (2005) 1.50

Isolated non-compaction cardiomyopathy. Dtsch Arztebl Int (2010) 1.49

Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging (2010) 1.49

Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace (2007) 1.46

Sepsis causes neuroinflammation and concomitant decrease of cerebral metabolism. J Neuroinflammation (2008) 1.46

Congenital heart defects in adulthood. Dtsch Arztebl Int (2011) 1.45

Spontaneous Brugada electrocardiogram patterns are rare in the German general population: results from the KORA study. Europace (2009) 1.45

MR Imaging of arrhythmogenic right ventricular cardiomyopathy: morphologic findings and interobserver reliability. Cardiology (2003) 1.44

Phytanic acid accumulation is associated with conduction delay and sudden cardiac death in sterol carrier protein-2/sterol carrier protein-x deficient mice. J Cardiovasc Electrophysiol (2004) 1.43

Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. Am Heart J (2007) 1.42

Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation. J Am Coll Cardiol (2007) 1.42

Respiratory gating in positron emission tomography: a quantitative comparison of different gating schemes. Med Phys (2007) 1.42